[{"orgOrder":0,"company":"Aeovian Pharmaceuticals","sponsor":"Hevolution Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"AV078","moa":"mTORC1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Aeovian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeovian Pharmaceuticals \/ Hevolution Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Aeovian Pharmaceuticals \/ Hevolution Foundation"}]

Find Clinical Drug Pipeline Developments & Deals by Aeovian Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Proceeds will support AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor, with Phase 2 trials planned for adult and pediatric patients suffering from TSC refractory epilepsy.

                          Product Name : AV078

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 28, 2024

                          Lead Product(s) : AV078

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase I

                          Sponsor : Hevolution Foundation

                          Deal Size : $50.0 million

                          Deal Type : Financing

                          blank